Clinical Interventions in Aging Dovepress Inappropriate Prescribing of Antithrombotic Therapy in Ethiopian Elderly Population Using Updated 2015 Stopp/start Criteria: a Cross-sectional Study
Clinical Interventions in Aging Dovepress Inappropriate Prescribing of Antithrombotic Therapy in Ethiopian Elderly Population Using Updated 2015 Stopp/start Criteria: a Cross-sectional Study
复制标题
使用 2015 年更新的停止/开始标准对埃塞俄比亚老年人群中老年 Dovepress 不恰当的抗血栓治疗处方进行临床干预：一项横断面研究
DOI：
--
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Admasu Belachew
中科院分区：
文献类型：
--
作者：
Henok Getachew Akshaya;Bhagavathula Tamrat;B. Abebe;Admasu Belachew
特此接受条款。只要该作品具有正确的归属，则无需获得 Dove Medical Press Limited 的任何进一步许可，即可将该作品用于非商业用途。如需将此成果用于商业用途，请参阅条款第 4.2 和第 5 段 背景：老年患者不适当使用抗血小板和抗凝药物会增加不良结果的风险。本研究的目的是评估住院老年患者抗血栓治疗处方不当的发生率。方法：在贡德尔大学医院进行了一项回顾性横断面、单中心研究。共有156名符合纳入/排除标准的住院老年患者纳入研究。老年人处方筛查工具/提醒医生正确治疗标准第二版的筛查工具应用于患者数据，以确定不适当处方 (IP) 的总数，包括潜在不适当药物和潜在处方遗漏。结果：在 156 名符合纳入标准的患者中总共鉴定出 70 个 IP。其中，36 种 (51.4%) 被老年人处方筛选工具标准确定为潜在不适当药物。每个患者的 IP 患病率表明，156 名患者中有 58 名 (37.2%) 至少接触过一种 IP。其中，32 名患者 (55.2%) 至少有一种可能不适当的药物，33 名患者 (56.9%) 至少有一种潜在的处方遗漏。因静脉血栓栓塞住院的患者（调整后优势比 [AOR] =29.87,1）不太可能接受 IP。 Charlson 合并症指数评分的增加与 IP 暴露的增加相关（AOR =0.60，95% CI，0.39-0.945）。仅接受抗血小板治疗的患者（AOR = 6.23，95% CI，1.90-20.37）中 IP 缺失的可能性比接受任何其他抗血栓治疗组的患者高出约六倍。结论：IPs 在主要因静脉血栓栓塞、卒中和急性冠状动脉综合征入院的老年患者以及仅接受抗血小板治疗的老年患者中较少见。然而，查尔森合并症指数较高的患者与 IP 暴露增加相关。我们的研究可以指导进一步的研究，以减少老年人抗血栓药物的高风险处方。
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms Background: Inappropriate use of antiplatelets and anticoagulants among elderly patients increases the risk of adverse outcomes. The aim of this study was to assess the prevalence of inappropriate prescribing of antithrombotic therapy in hospitalized elderly patients. Methods: A retrospective cross-sectional, single-center study was conducted at the Gondar University Hospital. A total of 156 hospitalized elderly patients fulfilling the inclusion/ exclusion criteria were included in the study. The Screening Tool for Older Person's Prescription/Screening Tool to Alert doctors to Right Treatment criteria version 2 were applied to patients' data to identify the total number of inappropriate prescribing (IPs) including potentially inappropriate medications and potential prescribing omissions. Results: A total of 70 IPs were identified in 156 patients who met the inclusion criteria. Of these, 36 (51.4%) were identified as potentially inappropriate medications by the Screening Tool for Older Person's Prescription criteria. The prevalence of IP per patient indicated that 58 of the 156 (37.2%) patients were exposed to at least one IP. Of these, 32 (55.2%) had at least one potentially inappropriate medication and 33 (56.9%) had at least one potential prescribing omission. Patients hospitalized due to venous thromboembolism (adjusted odds ratio [AOR] =29.87,1) were less likely to be exposed to an IP. An increase in Charlson comorbidity index score was associated with increased IP exposure (AOR =0.60, 95% CI, 0.39–0.945). IPs were about six times more likely to absent in patients prescribed with antiplatelet only therapy (AOR =6.23, 95% CI, 1.90–20.37) than those receiving any other groups of antithrombotics. Conclusion: IPs are less common in elderly patients primarily admitted due to venous throm-boembolism, stroke, and acute coronary syndrome, and those elderly patients prescribed with only antiplatelet. Patients with higher Charlson comorbidity index were, however, associated with increased IPs exposure. Our study may guide further research to reduce high-risk prescription of antithrombotics in the elderly.